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ICSM, THIRD ANNUAL SCIENTIFIC MEETING

PLENARY LECTURES
1.
DIABETES MELLITUS IS ASSOCIATED WITH HYPERREACTIVITY
OF SMOOTH MUSCLE CELLS DUE TO ALTERED SUBCELLULAR
CA2+ DISTRIBUTION IN THE HUMAN UTERINE ARTERY
Wolfgang F. Graier. Departments of Medical Biochemistry and Medical
Molecular Biology, Karl-Franzens University of Graz, Harrachgasse 21/III,
A-8010 Graz, Austria
Alterations of vascular smooth muscle function have been implicated in the
development of vascular complications and circulatory dysfunction in diabetes
mellitus. However, little is known on changes in smooth muscle contractility
and the intracellular mechanisms contributing to such altered responsiveness
in blood vessels from diabetic patients. Thus, smooth muscle reactivity to
increased K+, norepinephrine (NE) and phenylephrine (PE) and acetylcholineinduced endothelium-dependent relaxation were assessed in uterine arteries
from control individuals (CI) and diabetic patients (DM). Smooth muscle
sensitivity to K+, NE and PE was enhanced by 1.4-, 2.3- and 9.7-fold and
relaxation was reduced by 64% in vessels from DM. In addition, in freshly
isolated smooth muscle cells from DM an increased perinuclear Ca2+ signaling
to K+ (30 mmol/l: +73%; 30 mmol/l: +68%) and NE (300 nmol/l +86%; 10
mol/l +67%) was found, which promotes smooth muscle contraction. In
contrast, subplasmalemmal Ca 2+ response, which favors smooth muscle
relaxation due to activation of Ca2+-activated K+ channels, was reduced by
38% in DM, indicating a significant change in the subcellular Ca2+ distribution
in vascular smooth muscle cells during diabetes. In contrast to the altered
Ca2+ signaling found in freshly isolated cells from DM, in cultured smooth
muscle cells isolated from CI and DM no further difference in the Ca2+ signaling
to stimulation with either K+ or NE was found. Hence, production of superoxide
anions (ïO2-) in intact and endothelium-denuded arteries from DM was
increased by 150 and 136%, respectively. Incubation of freshly isolated smooth
muscle cells from CI with the ïO2- generating system xanthine oxidase/
hypoxanthine mimicked the effect of DM on subcellular Ca2+ distribution in
a SOD-sensitive manner. From these findings, we conclude that during diabetes
mellitus, smooth muscle reactivity is increased due to changes in subcellular
Ca2+ distribution upon cell activation. Increased ïO2- production seems to play
a crucial role in the alteration of smooth muscle function.

2.
THE PROBLEMS IN THE USE OF HERBAL AND NATURAL
SUSTANCES, WITH SPECIFIC EXAMPLE CONCERNING THE
CARDIOVASCULAR SYSTEM
Peter Pang*#, Christina Benishin*, Richard Lewanozuk*, and Jacqueline
Shan*. # The University of Hong Kong# and The University of Alberta, Canada*
Cardiovascular medicine is a fast moving field. During the last few decades,
advances in our understanding of the physiology, pathology and pharmacology
of the cardiac and vascular systems have been both stunning and
overwhelming. In the meanwhile, the use of drugs in the treatment of
cardiovascular diseases has experienced exponential growth. The awareness
of side effects of synthetic drugs has led to the exploration of the use of natural
or traditional medicine. What is needed is to bring together modern medicine
and natural or traditional medicine. This presentation attempts to provide an
example of how natural medicine can play a role in a new development in
cardiovascular science. PHF, parathyroid hypercytocalcic factor, is a newly
discovered hormone closely related to low-renin salt-sensitive hypertension.
Our recent studies discovered a natural substance preparation which acts as a
natural PHF antagonist. However, the use of natural medicine is currently
experiencing a creditability problem. This presentation will also describe
solutions to the problematic issues in natural medicine.
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3.
HEART VALVE REPLACEMENT SURGERY: PAST, PRESENT AND
FUTURE
Albert Starr, M.D. 9155 S.W. Barnes Road, Suite 240, Portland, OR 97225
U.S.A.

4.
A NEW STRATEGY IN THE TREATMENT OF HEART FAILURE RESULTS FROM THE MERIT-HF TRIAL
Finn Waagstein M.D. Ph.D. Professor in Cardiology. Department of
Cardiology, Sahlgrens Hospital, Göteborg University, Sweden

This abstract summarizes a 40 year evolution of heart valve replacement
surgery. In the late 1950s, the only surgery performed on a valve was a closed
mitral valvotomy. The first successful valve replacements with the StarrEdwards caged ball valve in 1960 were a milestone in the advancement of
heart surgery. Operative mortality for the first mitral series decreased steadily
from 50% in 1960 to near 0 within 5 years. Regression analysis showed that
long-term survival was related to intrinsic patient preoperative characteristics.
Other milestones in the advancement of heart surgery were the development
of the aortic homograft, the Bjork-Shiley valve, the Hancock porcine valve,
the St. Jude valve, pericardial and stentless valves. Porcine valves show a
wide variation in structural failure among series, ranging from 55% to 90%
and 50% to 80% at 10 years in the aortic and mitral positions, respectively.
Increased patient age has an importan t effect on failure rates.
Thromboembolism rates among series with a particular valve type vary greatly
due to non valve-related factors. Valvular thrombosis is a relatively rare
complication, and the majority of biological valve series have none, especially
in the aortic position. Infection rates for most series are below l% per year, for
both positions and classes of valves. There has been significant progress in
diminishing operative mortality and enhancing long-term survival over the
past 4 decades. Late complication rates are approximately similar with all
valve types. The future will require more durable tissue valves and safer
anticoagulation for mechanical valves, and perhaps less invasive surgery.

It has been well known for many years that betablockers exert antiischemic,
antiarrhythmic effects and reduce sudden death in ischemic heart disease.
Nevertheless cardiologists have been reluctant to use betablockers in patients
with congestive heart failure mainly for two reasons: Inotropic stimluation
was thought to be a more rational treatment in heart failure and there was
widespread fear that betablocker treatment might harm the patient. Hesitance
persisted despite several reports on improvement of myocardial function in
heart failure both from idiopathic dilated cardiomyopathy and ischemic heart
disease. The only way to overcome the sceptic attitude was to perform large
scale placebo-controlled trials with emphasis on both mortality, morbidity
and tolerability. Until 1999 no such study had enough statistical power to
prove effect on survival although metanalysis of the smaller studies indicates
a marked reduction in both mortality and morbidity. A study in dilated
cardiomyopathy with metoprolol showed that heart transplantation was
prevented. The rationale for betablocker treatment is thought to be reduction
in energy demand in combination with increased blood supply due to
lengthening of diastolic phase. This may lead to reduction in hibernation and
stunning resulting in functional recovery of myocardium and reversed
remodeling as shown in most studies. Additionally antiproliferative,
antioxidant and antiapoptic effects may prevent ongoing deterioration due to
celldeath. The first large survival trial with betablockers, the CIBIS II trial,
with a mixed population of ischemic and nonischemic patients NYHA class
II and IV showed a 34 % reduction in all cause mortality and 44 % reduction
in sudden cardiac death. The study did not achieve enough power to show
reduction in death due to congestive heart failure. The MERIT-HF trial
included 3991 patients from 14 different countries in two continents, with
approximately 50 % more patients than the CIBIS II trial. MERIT-HF trial
also included NYHA class II patients. The target dose was 200 mg metoprolol
per day in addition to baseline therapy with ACE-inhibitors. An average dose
of 159 mg metoprolol was reached. Overall mortality was reduced by 34 %,
cardiovascular mortality by 38, sudden death by 41 % and death due to
congestive heart failure by 49 %. The treatment effect was consistent in predefined subgroups such as males and females, elderly compared to younger,
ischemics versus nonischemics, diabetics versus nondiabetics, low versus high
ejection fraction, low versus high blood presssure and low versus high heart
rate and different NYHA classes. Sudden death was the dominating cause of
death in NYHA class II and III. There was a 25 % ( p = 0.08) reduction in
number of patients withdrawn from study due to heart failure and fewer patients
developed heart failure. Ten percent fewer patients were withdrawn from the
metoprolol group compared to placebo (NS). All cause mortality and
hospitalisation due to heart failure was reduced by 31 %. There was a significant
improvement in NYHA class and quality of life score. In conclusion: The
MERIT-HF trial confirmed that metoprolol reduces morbidity and mortality
significantly with an excellent tolerability. Combination therapy with
betablockers and ACE-inhibitors, and in more severe heart failure also
spirolactone, should therefore be mandatory in modern heart failure treatment.

